|Systematic (IUPAC) name|
|Metabolism||Hepatic, via Cytochrome P450 3A4|
|Half-life||Immediate release: 11.2 hours,
Extended release: 10.7–15.8 hours
|(what is this?)|
Alprazolam // or // (trade name Xanax //), available under other generic names, is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs. Alprazolam, like other benzodiazepines, binds to specific sites on the GABAAreceptor. Alprazolam is commonly used and FDA approved for the medical treatment of panic disorder, and anxiety disorders, such as generalized anxiety disorder (GAD) or social anxiety disorder (SAD). Alprazolam is available for oral administration in compressed tablet (CT) and extended-release capsule (XR) formulations. Alprazolam possesses anxiolytic, sedative, hypnotic, skeletal muscle relaxant, anticonvulsant, and amnestic properties.
Alprazolam has a fast onset of action and symptomatic relief. Ninety percent of peak effects are achieved within the first hour of using either in preparation for panic disorder, and full peak effects are achieved in 1.5 and 1.6 hours respectively. Peak benefits achieved for generalized anxiety disorder (GAD) may take up to a week. Tolerance to the anxiolytic/antipanic effects is controversial with some authoritative sources reporting the development of tolerance, and others reporting no development of tolerance; tolerance will however, develop to the sedative-hypnotic effects within a couple of days. Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction.
Alprazolam was first released by Upjohn (now a part of Pfizer). It is covered under U.S. Patent 3,987,052, which was filed on 29 October 1969, granted on 19 October 1976, and expired in September 1993. Alprazolam was released in 1981. The first approved indication was panic disorder and within two years of its original marketing Upjohn's Xanax became a blockbuster drug in the US. Presently, Alprazolam is the most prescribed and the most misused benzodiazepine on the U.S. retail market. The potential for misuse among those taking it for medical reasons is controversial with some expert reviews stating that the risk is low and similar to that of other benzodiazepine drugs and others stating that there is a substantial risk of abuse and dependence in both patients and non-medical users of alprazolam and that the pharmacological properties of alprazolam, high affinity binding, high potency, having a short elimination half-life as well as a rapid onset of action may increase the misuse potential of alprazolam. Compared to the large number of prescriptions, relatively few individuals increase their dose on their own initiative or engage in drug-seeking behavior. Alprazolam is classified as a schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA).
- 1 Medical uses
- 2 Pregnancy and lactation
- 3 Contraindications
- 4 Adverse effects
- 5 Detection in body fluids
- 6 Pharmacology
- 7 Pharmacokinetics
- 8 Forms of Alprazolam
- 9 Synthesis
- 10 Society and culture
- 11 References
- 12 External links
Alprazolam is mostly used to treat anxiety disorders, panic disorders, and nausea due to chemotherapy. The FDA label advises that the physician should periodically reassess the usefulness of the drug. Alprazolam may also be indicated for the treatment of generalized anxiety disorder, as well as for the treatment of anxiety conditions with co-morbid depression. Alprazolam is also often prescribed with instances of hypersomnia and co-morbid sleep deficits.
Alprazolam is effective in the relief of moderate to severe anxiety and panic attacks. However, it is not a first line treatment since the development of selective serotonin reuptake inhibitors, and alprazolam is no longer recommended in Australia for the treatment of panic disorder due to concerns regarding tolerance, dependence and abuse. Evidence supporting the effectiveness of alprazolam in treating panic disorder has been limited to 4 to 10 weeks. However, people with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit.
In the United States, alprazolam is FDA-approved for the treatment of panic disorder with or without agoraphobia. Alprazolam is recommended by the World Federation of Societies of Biological Psychiatry (WFSBP) for treatment-resistant cases of panic disorder where there is no history of tolerance or dependence.
Anxiety associated with depression is responsive to alprazolam. Demonstrations of the effectiveness by systematic clinical study are limited to 4 months duration for anxiety disorder. However, the research into antidepressant properties of alprazolam is of poor quality and only assessed the short-term effects of alprazolam against depression. In one study, some long term, high-dosage users of alprazolam developed reversible depression. In the US, alprazolam is FDA-approved for the management of anxiety disorders (a condition corresponding most closely to the APA Diagnostic and Statistical Manual DSM-IV-TR diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. In the UK, alprazolam is recommended for the short-term treatment (2–4 weeks) of severe acute anxiety.
Nausea due to chemotherapy
Pregnancy and lactation
Benzodiazepines cross the placenta, enter into the fetus and are also excreted with breast milk. The use of benzodiazepines during pregnancy or lactation has potential risks. The use of alprazolam in pregnancy is believed to be associated with congenital abnormalities. Diazepam and chlordiazepoxide have a better safety profile in pregnancy than alprazolam.
Women who are pregnant or are planning on becoming pregnant should avoid starting alprazolam. Use in the last trimester may cause fetal drug dependence and withdrawal symptoms in the post-natal period as well as neonatal flaccidity and respiratory problems. However, in long-term users of benzodiazepines abrupt discontinuation due to concerns of teratogenesis has a high risk of causing extreme withdrawal symptoms and a severe rebound effect of the underlying mental health disorder. Spontaneous abortions may also result from abrupt withdrawal of psychotropic medications including benzodiazepines.
Benzodiazepines, including alprazolam, are known to be excreted in human milk. Chronic administration of diazepam to nursing mothers has been reported to cause their infants to become lethargic and to lose weight.
Benzodiazepines require special precaution if used in children and in alcohol- or drug-dependent individuals. Particular care should be taken in pregnant or elderly patients, patients with substance abuse history, particularly alcohol dependence and patients with comorbid psychiatric disorders. Use of alprazolam should be avoided or carefully monitored by medical professionals in individuals with the following conditions: myasthenia gravis, acute narrow-angle glaucoma, severe liver deficiencies (e.g., cirrhosis), severe sleep apnea, pre-existing respiratory depression, marked neuromuscular respiratory weakness including unstable myasthenia gravis, acute pulmonary insufficiency, chronic psychosis, hypersensitivity or allergy to alprazolam or other drugs in the benzodiazepine class, borderline personality disorder (may induce suicidality and dyscontrol).
Like all central nervous system depressants, including alcohol, alprazolam in larger-than-normal doses can cause significant deterioration in alertness, combined with increased feelings of drowsiness, especially in those unaccustomed to the drug's effects. People driving or conducting activities that require vigilance should exercise caution in using alprazolam or any other depressant until they know how it affects them.
Elderly individuals should be cautious in the use of alprazolam due to the possibility of increased susceptibility to side-effects, especially loss of coordination and drowsiness.
Allergic reactions are unlikely to occur. The only common side effect is sleepiness when treatment is initiated.
Possible side effects include:
- Jaundice (very rare)
- Hallucinations (rare)
- Dry mouth (infrequent)
- Ataxia, slurred speech
- Suicidal ideation (rare)
- Urinary retention (infrequent)
- Skin rash, respiratory depression, constipation
- Anterograde amnesia and concentration problems
- Drowsiness, dizziness, lightheadedness, fatigue, unsteadiness and impaired coordination, vertigo
Although unusual, the following paradoxical reactions have been shown to occur:
- Rage, hostility
- Twitches and tremor
- Mania, agitation, hyperactivity and restlessness
Food and drug interactions
Alprazolam is primarily metabolised via CYP3A4. Combining CYP3A4 inhibitors such as cimetidine, erythromycin, fluoxetine, fluvoxamine, itraconazole, ketoconazole, nefazodone, propoxyphene, and ritonavir delay the hepatic clearance of alprazolam, which may result in excessive accumulation of alprazolam. This may result in exacerbation of its adverse effect profile.
Imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day. Combined oral contraceptive pills reduce the clearance of alprazolam, which may lead to increased plasma levels of alprazolam and accumulation.
Alcohol is one of the most important and common interactions. Alcohol and benzodiazepines such as alprazolam taken in combination have a synergistic effect on one another, which can cause severe sedation, behavioral changes, and intoxication. The more alcohol and alprazolam taken the worse the interaction. Combination of alprazolam with the herb kava can result in the development of a semi-comatose state. Hypericum conversely can lower the plasma levels of alprazolam and reduce its therapeutic effect.
Overdoses of alprazolam can be mild to severe depending on how much of the drug is taken and any other drugs that have been taken.
- Somnolence (sleepy state)
- Hypotension (low blood pressure)
- Orthostatic hypotension (fainting while standing up too quickly)
- Hypoventilation (shallow breathing)
- Impaired motor functions
- Coma and death are possible if alprazolam is combined with other substances.
In a study of deaths in Palm Beach County where the drug alprazolam was detected, approximately 50% of cases were attributed to poly-drug use (the combined toxicity of two or more drugs). The majority of these cases included either cocaine or methadone. Alprazolam alone caused only 1% of the deaths. These results indicate alprazolam has a very low incidence of causing death when taken alone.
Dependence and withdrawal
Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA gamma-amino-butyric acid receptor. When bound to these sites, which are referred to as benzodiazepine receptors, it modulates the effect of GABA A receptors and, thus, GABAergic neurons. Long-term use causes adaptive changes in the benzodiazepine receptors, making them less sensitive to stimulation and less powerful in their effects.
Not all withdrawal effects are evidence of true dependence or withdrawal. Recurrence of symptoms such as anxiety may simply indicate that the drug was having its expected anti-anxiety effect and that, in the absence of the drug, the symptom has returned to pretreatment levels. If the symptoms are more severe or frequent, the patient may be experiencing a rebound effect due to the removal of the drug. Either of these can occur without the patient's actually being drug-dependent.
Alprazolam and other benzodiazepines may also cause the development of physical dependence, tolerance, and benzodiazepine withdrawal symptoms during rapid dose reduction or cessation of therapy after long-term treatment. There is a higher chance of withdrawal reactions if the drug is administered in a higher dosage than recommended, or if a patient stops taking the medication altogether without slowly allowing the body to adjust to a lower-dosage regimen.
In 1992, Romach and colleagues reported that dose escalation is not a characteristic of long-term alprazolam users, and that the majority of long-term alprazolam users change their initial pattern of regular use to one of symptom control only when required.
Some common symptoms of alprazolam discontinuation include malaise, weakness, insomnia, tachycardia, lightheadedness, and dizziness.
Patients taking a dosing regimen larger than 4 mg per day have an increased potential for dependence. This medication may cause withdrawal symptoms upon abrupt withdrawal or rapid tapering, which in some cases have been known to cause seizures. The discontinuation of this medication may also cause a reaction called rebound anxiety.
Delirium similar to that produced by the tropane alkaloids (gaba antagonists) of Datura (scolopamine and atropine) and seizures have been anecdotally reported in the medical literature from abrupt alprazolam discontinuation.
In a 1983 study of patients who had taken long-acting benzodiazepines, e.g., clorazepate, for extended periods, the medications were stopped abruptly. Only 5% of patients who had been taking the drug for less than 8 months demonstrated withdrawal symptoms, but 43% of those who had been taking them for more than 8 months did. With alprazolam – a short-acting benzodiazepine – taken for 8 weeks, 35% of patients experienced significant rebound anxiety. To some degree, these older benzodiazepines are self-tapering.
The benzodiazepines diazepam (Valium) and oxazepam (Serepax) have been found to produce fewer withdrawal reactions than alprazolam (Xanax), temazepam (Restoril/Normison), or lorazepam (Temesta/Ativan). Factors that determine the risk of psychological dependence or physical dependence and the severity of the benzodiazepine withdrawal symptoms experienced during dose reduction of alprazolam include: dosage used, length of use, frequency of dosing, personality characteristics of the individual, previous use of cross-dependent/cross-tolerant drugs (alcohol or other sedative-hypnotic drugs), current use of cross-dependent/-tolerant drugs, use of other short-acting, high-potency benzodiazepines, and method of discontinuation.
Detection in body fluids
Alprazolam may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma alprazolam concentrations are usually in a range of 10–100 μg/L in persons receiving the drug therapeutically, 100–300 μg/L in those arrested for impaired driving and 300–2000 μg/L in victims of acute overdosage. Most commercial immunoassays for the benzodiazepine class of drugs will cross-react with alprazolam, but confirmation and quantitation is usually performed using chromatographic techniques.
Alprazolam is classed as a high-potency benzodiazepine and is a triazolobenzodiazepine, namely a benzodiazepine with a triazole ring attached to its structure. Benzodiazepines produce a variety of therapeutic and adverse effects by binding to the benzodiazepine receptor site on the GABAA receptor and modulating the function of the GABA receptor, the most prolific inhibitory receptor within the brain. The GABA chemical and receptor system mediates inhibitory or calming effects of alprazolam on the nervous system. The GABAA receptor is made up of 5 subunits out of a possible 19, and GABAA receptors made up of different combinations of subunits, have different properties, different locations within the brain, and, importantly, different activities with regard to benzodiazepines. Benzodiazepines and in particular alprazolam causes a marked suppression of the hypothalamicpituitary-adrenal axis. The therapeutic properties of alprazolam are similar to other benzodiazepines and include anxiolytic, anticonvulsant, muscle relaxant, hypnotic and amnesic.
Following oral administration, alprazolam is readily absorbed. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.5 to 3.0 mg, peak levels of 8.0 to 37 ng/mL were observed. Using a specific assay methodology, the mean plasma elimination half-life of alprazolam has been found to be about 11.2 hours (range: 6.3 to 26.9 hours) in healthy adults.
In vitro, alprazolam is bound (80 percent) to human serum protein. Serum albumin accounts for the majority of the binding.
Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (Cyp3A4), to two major metabolites in plasma: 4-hydroxyalprazolam and α- hydroxyalprazolam. A benzophenone derived from alprazolam is also found in humans. Half-lives are similar to that of alprazolam. The plasma concentrations of 4-hydroxyalprazolam and α-hydroxyalprazolam relative to unchanged alprazolam concentration were always less than 4%. The reported relative potencies in benzodiazepines receptor binding experiments and in animals models of induced seizure inhibition are 0.2 and 0.66, respectively, for 4-hydroxyalprazolam and α-hydroxyalprazolam. Such low concentrations and lesser potencies of 4-hydroxyalprazolam and α-hydroxyalprazolam suggest that they are unlikely to contribute much to the pharmacological effects of alprazolam. The benzophenone metabolite is essentially inactive.
Alprazolam and its metabolites are excreted primarily in the urine.
Forms of Alprazolam
Alprazolam regular release and orally disintegrating tablets are available as 0.25 mg, 0.5 mg, 1 mg, 2 mg strength tablets.
Alprazolam extended release tablets are available as 0.5 mg, 1 mg, 2 mg, and 3 mg strength tablets.
Alprazolam oral solutions are available as 0.5 mg/5 mL and as 1 mg/1 mL oral solutions.
- Active ingredient: alprazolam
- Inactive ingredients: microcrystalline cellulose, corn starch, docusate sodium, povidone, sodium starch glycollate, lactose monohydrate, magnesium stearate, colloidal silicon dioxide and sodium benzoate. In addition, the 0.25 mg tablet contains D&C Yellow No. 10 and the 0.5 mg tablet contains FD&C Yellow No. 6 and D&C Yellow No. 10
Alprazolam is a chemical analog of triazolam that differs by the absence of a chlorine atom in the o-position of the 6-phenyl ring. The same scheme that was used to make triazolam can be used to make alprazolam, with the exception that it begins with 2-amino-5-chlorobenzophenone.
Another way of making alprazolam has been suggested, which comes from 2,6-dichloro-4-phenylquinoline, the reaction of which with hydrazine gives 6-chloro-2-hydrazino-4-phenylquinoline. Boiling this with triethyl orthoacetate in xylene leads to the heterocyclization into a triazole derivative. The resulting product undergoes oxidative cleavage using sodium periodate and ruthenium dioxide in an acetone–water system to give 2-[4-(3′-methyl-1,2,4-triazolo)]-5-chlorobenzophenone. Oxymethylation of the last using formaldehyde and subsequent substitution of the resulting hydroxyl group by phosphorus tribromide,gives 2-[4-(3′-methyl-5′-bromomethyl-1,2,4-triazolo)]-5-chlorobenzophenone. Substitution of the bromine atom with an amino group using ammonia and the spontaneous, intramolecular heterocyclization following that reaction gives alprazolam.
Society and culture
There is a risk of misuse and dependence in both patients and non-medical users of alprazolam; the pharmacological properties of alprazolam such as high affinity binding, high potency, being short-acting and having a rapid onset of action increase the abuse potential of alprazolam. The physical dependence and withdrawal syndrome of alprazolam also adds to the addictive nature of alprazolam. In the small subgroup of individuals who escalate their doses there is usually a history of alcohol or other substance use disorders. Despite this, most prescribed alprazolam users do not misuse their medication, and the long-term use of benzodiazepines does not generally correlate with the need for dose escalation. However, based on US findings from the Treatment Episode Data Set (TEDS), an annual compilation of patient characteristics in substance abuse treatment facilities in the United States, admissions due to "primary tranquilizer" (including, but not limited to, benzodiazepine-type) drug use increased 79% from 1992 to 2002, suggesting that misuse of benzodiazepines may be on the rise. The New York Times also reported in 2011 that "The Centers for Disease Control and Prevention last year reported an 89 percent increase in emergency room visits nationwide related to nonmedical benzodiazepine use between 2004 and 2008."
Alprazolam is one of the most commonly prescribed and misused benzodiazepines in the United States. A large-scale nationwide U.S. government study conducted by SAMHSA found that, in the U.S., benzodiazepines are recreationally the most frequently used pharmaceuticals due to their widespread availability, accounting for 35% of all drug-related visits to hospital emergency and urgent care facilities. Men and women are equally likely to use benzodiazepines recreationally. The report found that alprazolam is the most common benzodiazepine for recreational use followed by clonazepam, lorazepam, and diazepam. The number of emergency room visits due to benzodiazepines increased by 36% between 2004 and 2006.
Regarding the significant increases detected, it is worthwhile to consider that the number of pharmaceuticals dispensed for legitimate therapeutic uses may be increasing over time, and DAWN estimates are not adjusted to take such increases into account. Nor do DAWN estimates take into account the increases in the population or in ED use between 2004 and 2006.
Alprazolam, along with other benzodiazepines, is often used with other recreational drugs. These uses include aids to relieve the panic or distress of dysphoric ("bad trip") reactions to psychedelic drugs, such as LSD, and the drug-induced agitation and insomnia in the "comedown" stages of stimulant use, such as amphetamine, cocaine, and phencyclidine allowing sleep. Alprazolam may also be used in conjunction with other depressant drugs, such as alcohol, heroin or other opiates, in an attempt to enhance the psychological effect of these drugs.
The poly-drug use of powerful depressant drugs poses the highest level of health concerns due to a significant increase in the likelihood of experiencing an overdose which may result in fatal respiratory depression.
A 1990 study claimed that diazepam has a higher misuse potential relative to other benzodiazepines, and that some data suggests that alprazolam and lorazepam resemble diazepam in this respect.
Anecdotally injection of alprazolam has been reported, causing dangerous damage to blood vessels, closure of blood vessels (embolization) and decay of muscle tissue (rhabdomyolysis). Alprazolam is practically not soluble in water, when crushed in water it will not fully dissolve (40 µg/ml of H2O at pH 7). There have also been anecdotal reports of alprazolam being snorted. Due to the low weight of a dose, alprazolam in one case was found to be distributed on blotter paper in a manner similar to LSD.
Slang terms for alprazolam vary from place to place. Some of the more common terms are shortened versions of the trade name "Xanax", such as Xanbars or Zannies; references to their drug classes, such as benzos or downers; or remark upon their shape or color (most commonly a straight, perforated tablet or an oval-shaped pill): bars, Z-bars, footballs, planks, blues, or blue footballs.
Alprazolam is available in English-speaking countries under the following brand names:
- Alprax, Alprocontin, Alzam, Alzolam, Anzilum, Apo-Alpraz, Kalma, Mylan-Alprazolam, Niravam, Novo-Alprazol, Nu-Alpraz, Pacyl, Restyl, Tranax, Trika, Xycalm, Xanax, Xanor, Zolam, Zopax, Helex.
As of December 2013, in anticipation of the rescheduling of alprazolam to Schedule 8 in Australia—Pfizer Australia announced they would be discontinuing the Xanax brand in Australia as it is no longer commercially viable.
In the United States, alprazolam is a prescription drug and is assigned to Schedule IV of the Controlled Substances Act by the Drug Enforcement Administration. Under the UK drug misuse classification system benzodiazepines are class C drugs (Schedule 4). In the UK, alprazolam is not available on the NHS and can only be obtained on a private prescription. Internationally, alprazolam is included under the United Nations Convention on Psychotropic Substances as Schedule IV. In Ireland, alprazolam is a Schedule 4 medicine. In Sweden, alprazolam is a prescription drug in List IV (Schedule 4) under the Narcotics Drugs Act (1968). In the Netherlands, alprazolam is a List 2 substance of the Opium Law and is available for prescription. In Australia, alprazolam was originally a Schedule 4 (Prescription Only) medication; however, as of February 2014, it has become a Schedule 8 medication, subjecting it to more rigorous prescribing requirements.
- "Xanax (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications". RxList. First DataBank. July 2008.
- "Xanax XR (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications". RxList. First DataBank. July 2008.
- Work Group on Panic Disorder (January 2009). APA Practice Guideline for the Treatment of Patients With Panic Disorder (2nd ed.). doi:10.1176/appi.books.9780890423905.154688.
- "FDA approved labeling for Xanax revision 08/23/2011" (PDF). Federal Drug Administration. 2011-08-23. p. 4. Retrieved 2011-09-14. "Anxiety Disorders – XANAX Tablets (alprazolam) are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSMIII-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic... Panic Disorder – XANAX is also indicated for the treatment of panic disorder, with or without agoraphobia... Demonstrations of the effectiveness of XANAX by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis without any apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient."
- Mandrioli, R.; Mercolini, L.; Raggi, M. A. (2008). "Benzodiazepine Metabolism: An Analytical Perspective". Current Drug Metabolism 9 (8): 827–844. doi:10.2174/138920008786049258. PMID 18855614.
- Sheehan, D. V.; Sheehan, K. H.; Raj, B. A. (2007). "The Speed of Onset of Action of Alprazolam-XR Compared to Alprazolam-CT in Panic Disorder". Psychopharmacology Bulletin 40 (2): 63–81. PMID 17514187.
- Smith, R. B.; Kroboth, P. D.; Vanderlugt, J. T.; Phillips, J. P.; Juhl, R. P. (1984). "Pharmacokinetics and Pharmacodynamics of Alprazolam after Oral and IV Administration". Psychopharmacology 84 (4): 452–456. doi:10.1007/bf00431449. PMID 6152055.
- Verster, J. C.; Volkerts, E. R. (2004). "Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature" (PDF). CNS Drug Reviews 10 (1): 45–76. doi:10.1111/j.1527-3458.2004.tb00003.x. PMID 14978513.
- Tampi, R. R.; Muralee, S.; Weder, N. D.; Penland, H., eds. (2008). Comprehensive Review of Psychiatry. Philadelphia, PA: Wolters Kluwer / Lippincott Williams & Wilkins Health. p. 226. ISBN 978-0-7817-7176-4. Retrieved 2014-01-22.
- Moylan, S.; Giorlando, F.; Nordfjærn, T.; Berk, M. (2012). "The Role of Alprazolam for the Treatment of Panic Disorder in Australia" (PDF). The Australian and New Zealand Journal of Psychiatry 46 (3): 212–224. doi:10.1177/0004867411432074. PMID 22391278.
- Pavuluri, M. N.; Janicak, P. G.; Marder, S. R. (2010). Principles and Practice of Psychopharmacotherapy (5th ed.). Philadelphia, PA: Wolters Kluwer Health / Lippincott Williams & Wilkins. p. 535. ISBN 978-1-60547-565-3. Retrieved 2014-01-22.
- Galanter, M. (2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (4th ed.). American Psychiatric Publishing. p. 222. ISBN 978-1-58562-276-4. Retrieved 2014-01-22.
- Walker, S. (1996). A Dose of Sanity: Mind, Medicine, and Misdiagnosis. New York: John Wiley & Sons. pp. 64–65. ISBN 978-0-471-19262-6.
- Langreth, Robert; Herper, Matthew (2010-05-11). "In Pictures: The Most Popular Prescription Drugs". Forbes.
- "Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits" (PDF). U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. 2006. Retrieved 13 February 2012.
- "Alprazolam". The American Society of Health-System Pharmacists. Archived from the original on 15 May 2011. Retrieved 3 April 2011.
- "DEA Brief Benzodiazepines". Archived from the original on 2009-03-12. Retrieved 1 October 2011. "Given the millions of prescriptions written for benzodiazepines (about 100 million in 1999), relatively few individuals increase their dose on their own initiative or engage in drug-seeking behavior."
- "Xanax (Alprazolam) Drug Information: Indications, Dosage and How Supplied – Prescribing Information". Rxlist.com. RxList. Retrieved 2013-09-20.
- "Xanax (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications at RxList". RxList. First DataBank. July 2008.
- Bandelow, B.; Zohar, J.; Hollander, E.; Kasper, S.; Möller, H. J.; WFSBP Task Force On Treatment Guidelines For Anxiety, O. C. P. S. D. (2002). "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders". World Journal of Biological Psychiatry 3 (4): 171–199. doi:10.3109/15622970209150621. PMID 12516310.
- van Marwijk, H.; Allick, G.; Wegman, F.; Bax, A.; Riphagen, I. I. (2012). van Marwijk, Harm, ed. "Alprazolam for depression". Cochrane Database Syst Rev 7: CD007139. doi:10.1002/14651858.CD007139.pub2. PMID 22786504.
- Lydiard, R. B.; Laraia, M. T.; Ballenger, J. C.; Howell, E. F. (May 1987). "Emergence of Depressive Symptoms in Patients Receiving Alprazolam for Panic Disorder". The American Journal of Psychiatry 144 (5): 664–665. PMID 3578580.
- "Xanax". Netdoctor.co.uk. NetDoctor. 2006-10-01. Archived from the original on 9 August 2007. Retrieved 2007-08-02.
- "Alprazolam". British National Formulary. 2007. Retrieved 3 August 2007.
- "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings". RxList.com. United States: RxList. July 2008. p. 4.
- Iqbal, M. M.; Sobhan, T.; Ryals, T. (2002). "Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant". Psychiatric Services 53 (1): 39–49. doi:10.1176/appi.ps.53.1.39. PMID 11773648.
- García-Algar, Ó.; López-Vílchez, M. Á.; Martín, I.; Mur, A.; Pellegrini, M.; Pacifici, R.; Rossi, S.; Pichini, S. (2007). "Confirmation of Gestational Exposure to Alprazolam by Analysis of Biological Matrices in a Newborn with Neonatal Sepsis". Clinical Toxicology 45 (3): 295–298. doi:10.1080/15563650601072191. PMID 17453885.
- Einarson, A.; Selby, P.; Koren, G. (2001). "Abrupt Discontinuation of Psychotropic Drugs During Pregnancy: Fear of Teratogenic Risk and Impact of Counselling" (PDF). Journal of Psychiatry and Neuroscience 26 (1): 44–48. PMC 1408034. PMID 11212593.
- Oo, C. Y.; Kuhn, R. J.; Desai, N.; Wright, C. E.; McNamara, P. J. (1995). "Pharmacokinetics in Lactating Women: Prediction of Alprazolam Transfer into Milk". British Journal of Clinical Pharmacology 40 (3): 231–236. doi:10.1111/j.1365-2125.1995.tb05778.x. PMC 1365102. PMID 8527284.
- "Alprazolam – Oral (Xanax) Side Effects, Medical Uses, and Drug Interactions". Medicinenet.com. MedicineNet. July 2005. Archived from the original on 18 December 2008. Retrieved 2008-12-07.
- "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings". RxList.com. RxList. July 2008. p. 8. Archived from the original on 5 December 2008. Retrieved 2008-12-07.
- Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, A. A. et al. (2009). "Benzodiazepine Dependence: Focus on Withdrawal Syndrome". Annales Pharmaceutiques Françaises 67 (6): 408–413. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- Hori, A. (1998). "Pharmacotherapy for Personality Disorders". Psychiatry and Clinical Neurosciences 52 (1): 13–19. doi:10.1111/j.1440-1819.1998.tb00967.x. PMID 9682928.
- Gardner, D. L.; Cowdry, R. W. (1985). "Alprazolam-Induced Dyscontrol in Borderline Personality Disorder". American Journal of Psychiatry 142 (1): 98–100. PMID 2857071.
- "Alprazolam". mentalhealth.com. 2007. Retrieved 3 August 2007.
- Kozená, L.; Frantik, E.; Horváth, M. (1995). "Vigilance Impairment after a Single Dose of Benzodiazepines". Psychopharmacology 119 (1): 39–45. doi:10.1007/BF02246052. PMID 7675948.
- Michel, L.; Lang, J. P. (2003). "Benzodiazépines et passage à l'acte criminel" [Benzodiazepines and Forensic Aspects]. Encephale (in French) 29 (6): 479–485. PMID 15029082. Retrieved 9 April 2013.
- Noyes, R.; DuPont, R. L.; Pecknold, J. C.; Rifkin, A.; Rubin, R. T.; Swinson, R. P. et al. (1988). "Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial. II. Patient Acceptance, Side Effects, and Safety". Archives of General Psychiatry 45 (5): 423–428. doi:10.1001/archpsyc.1988.01800290037005. PMID 3358644.
- "Complete Alprazolam Information". Drugs.com. Archived from the original on 5 August 2007. Retrieved 2 August 2007.
- Elie, R.; Lamontagne, Y. (1984). "Alprazolam and Diazepam in the Treatment of Generalized Anxiety". Journal of Clinical Psychopharmacology 4 (3): 125–129. doi:10.1097/00004714-198406000-00002. PMID 6145726.
- Cassano, G. B.; Toni, C.; Petracca, A.; Deltito, J.; Benkert, O.; Curtis, G. et al. (1994). "Adverse Effects Associated with the Short-term Treatment of Panic Disorder with Imipramine, Alprazolam or Placebo". European Neuropsychopharmacology 4 (1): 47–53. doi:10.1016/0924-977X(94)90314-X. PMID 8204996.
- Kravitz, H. M.; Fawcett, J.; Newman, A. J. (1993). "Alprazolam and Depression: A Review of Risks and Benefits". Journal of Clinical Psychiatry 54 (Supplement): 78–84; discussion 85. PMID 8262892.
- "Alprazolam Side Effects, Interactions and Information". Drugs.com. Archived from the original on 19 August 2007. Retrieved 2 August 2007.
- Rawson, N. S.; Rawson, M. J. (1999). "Acute Adverse Event Signalling Scheme Using the Saskatchewan Administrative Health Care Utilization Datafiles: Results for Two Benzodiazepines". Canadian Journal of Clinical Pharmacology 6 (3): 159–166. PMID 10495368.
- "Alprazolam – Complete Medical Information Regarding This Treatment of Anxiety Disorders". Medicinenet.com. MedicineNet. Retrieved 2 August 2007.
- Barbee, J. G. (1993). "Memory, Benzodiazepines, and Anxiety: Integration of Theoretical and Clinical Perspectives". The Journal of Clinical Psychiatry 54 (Suppl): 86–97; discussion 98–101. PMID 8262893.
- Rapaport, M.; Braff, D. L. (1985). "Alprazolam and Hostility". American Journal of Psychiatry 142 (1): 146. PMID 2857070.
- Béchir, M.; Schwegler, K.; Chenevard, R.; Binggeli, C.; Caduff, C.; Büchi, S. et al. (2007). "Anxiolytic Therapy with Alprazolam Increases Muscle Sympathetic Activity in Patients with Panic Disorders". Autonomic Neuroscience 134 (1–2): 69–73. doi:10.1016/j.autneu.2007.01.007. PMID 17363337.
- Arana, G. W.; Pearlman, C.; Shader, R. I. (1985). "Alprazolam-Induced Mania: Two Clinical Cases". American Journal of Psychiatry 142 (3): 368–369. PMID 2857534.
- Strahan, A.; Rosenthal, J.; Kaswan, M.; Winston, A. (1985). "Three Case Reports of Acute Paroxysmal Excitement Associated with Alprazolam Treatment". American Journal of Psychiatry 142 (7): 859–861. PMID 2861755.
- Reddy, J.; Khanna, S.; Anand, U.; Banerjee, A. (1996). "Alprazolam-Induced Hypomania". Australia and New Zealand Journal of Psychiatry 30 (4): 550–552. doi:10.3109/00048679609065031. PMID 8887708.
- Otani, K. (2003). "Cytochrome P450 3A4 and Benzodiazepines". Seishin Shinkeigaku Zasshi (in Japanese) 105 (5): 631–642. PMID 12875231.
- Dresser, G. K.; Spence, J. D.; Bailey, D. G. (2000). "Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition". Clinical Pharmacokinetics 38 (1): 41–57. doi:10.2165/00003088-200038010-00003. PMID 10668858.
- Greenblatt, D. J.; Wright, C. E. (1993). "Clinical Pharmacokinetics of Alprazolam. Therapeutic Implications". Clinical Pharmacokinetics 24 (6): 453–471. doi:10.2165/00003088-199324060-00003. PMID 8513649.
- Wang, J. S.; Chase, C. L. (2003). "Pharmacokinetics and Drug Interactions of the Sedative Hypnotics" (PDF). Psychopharmacological Bulletin 37 (1): 10–29. doi:10.1007/BF01990373. PMID 14561946. Archived from the original on 2007-07-09.
- "FDA SPL Approved Application Filing for NDC Code 0228-3083 (Alprazolam by Actavis Elizabeth LLC)". "AD535DF9-6361-460D-9648-450A0A6F61CD.xml".
- Back, D. J.; Orme, M. L. (1990). "Pharmacokinetic Drug Interactions with Oral Contraceptives". Clinical Pharmacokinetics 18 (6): 472–484. doi:10.2165/00003088-199018060-00004. PMID 2191822.
- Izzo, A. A.; Ernst, E. (2001). "Interactions between Herbal Medicines and Prescribed Drugs: A Systematic Review". Drugs 61 (15): 2163–2175. doi:10.2165/00003495-200161150-00002. PMID 11772128.
- Izzo, A. A. (2004). "Drug Interactions with St. John's Wort (Hypericum perforatum): A Review of the Clinical Evidence". International Journal of Clinical Pharmacology and Therapeutics 42 (3): 139–148. doi:10.5414/CPP42139. PMID 15049433.
- Madabushi, R.; Frank, B.; Drewelow, B.; Derendorf, H.; Butterweck, V. (2006). "Hyperforin in St. John's Wort Drug Interactions". European Journal of Clinical Pharmacology 62 (3): 225–233. doi:10.1007/s00228-006-0096-0. PMID 16477470.
- Izzo, A. A.; Ernst, E. (2009). "Interactions between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review". Drugs 69 (13): 1777–1798. doi:10.2165/11317010-000000000-00000. PMID 19719333.
- Isbister, G. K.; O'Regan, L.; Sibbritt, D.; Whyte, I. M. (2004). "Alprazolam is Relatively more Toxic than other Benzodiazepines in Overdose". British Journal of Clinical Pharmacology 58 (1): 88–95. doi:10.1111/j.1365-2125.2004.02089.x. PMC 1884537. PMID 15206998.
- Wolf, B. C.; Lavezzi, W. A.; Sullivan, L. M.; Middleberg, R. A.; Flannagan, L. M. (2005). "Alprazolam-Related Deaths in Palm Beach County". American Journal of Forensic Medicine and Pathology 26 (1): 24–27. doi:10.1097/01.paf.0000153994.95642.c1. PMID 15725773.
- Stahl, S. (1996). Essential Pharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press. ISBN 0-521-42620-0.[page needed]
- Juergens, S. M.; Morse, R. M. (1988). "Alprazolam Dependence in seven Patients". The American Journal of Psychiatry 145 (5): 625–627. PMID 3258735.
- Klein, E. (2002). "The Role of Extended-Release Benzodiazepines in the Treatment of Anxiety: A Risk-Benefit Evaluation with a Focus on Extended-Release Alprazolam". The Journal of Clinical Psychiatry 63 (Suppl 14): 27–33. PMID 12562116.
- Ashton, Heather (August 2002). "The Ashton Manual – Benzodiazepines: How They Work and How to Withdraw". Benzo.org.uk. Retrieved 2008-10-31.
- Closser, M. H.; Brower, K. J. (1994). "Treatment of Alprazolam Withdrawal with Chlordiazepoxide Substitution and Taper". Journal of Substance Abuse Treatment 11 (4): 319–323. doi:10.1016/0740-5472(94)90042-6. PMID 7966502.
- Romach, M. K.; Somer, G. R.; Sobell, L. C.; Sobell, M. B.; Kaplan, H. L.; Sellers, E. M. (1992). "Characteristics of Long-Term Alprazolam Users in the Community". Journal of Clinical Psychopharmacology 12 (5): 316–321. doi:10.1097/00004714-199210000-00004. PMID 1479048.
- Fyer, A. J.; Liebowitz, M. R.; Gorman, J. M.; Campeas, R.; Levin, A.; Davies, S. O. et al. (1987). "Discontinuation of Alprazolam Treatment in Panic Patients". American Journal of Psychiatry 144 (3): 303–308. PMID 3826428. Retrieved 2008-12-10.
- Breier, A.; Charney, D. S.; Nelson, J. C. (1984). "Seizures Induced by Abrupt Discontinuation of Alprazolam". The American Journal of Psychiatry 141 (12): 1606–1607. PMID 6150649.
- Noyes Jr, R.; Perry, P. J.; Crowe, R. R.; Coryell, W. H.; Clancy, J.; Yamada, T.; Gabel, J. (1986). "Seizures following the withdrawal of alprazolam". The Journal of Nervous and Mental Disease 174 (1): 50–52. doi:10.1097/00005053-198601000-00009. PMID 2867122.
- Levy, A. B. (1984). "Delirium and Seizures due to Abrupt Alprazolam Withdrawal: Case Report". The Journal of Clinical Psychiatry 45 (1): 38–39. PMID 6141159.
- Schatzberg, A.; DeBattista, C. (2003). Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Pub. p. 391. ISBN 1-58562-209-5. Retrieved 2014-01-22.
- Wolf, B.; Griffiths, R. R. (1991). "Physical Dependence on Benzodiazepines: Differences Within the Class". Drug and Alcohol Dependence 29 (2): 153–156. doi:10.1016/0376-8716(91)90044-Y. PMID 1686752.
- Higgitt, A.; Fonagy, P.; Lader, M. (1988). "The Natural History of Tolerance to the Benzodiazepines". Psychological Medicine. Monograph Supplement 13: 1–55. doi:10.1017/S0264180100000412. PMID 2908516.
- Jones, A. W.; Holmgren, A.; Kugelberg, F. C. (2007). "Concentrations of Scheduled Prescription Drugs in Blood of Impaired Drivers: Considerations for Interpreting the Results". Therapeutic Drug Monitoring 29 (2): 248–260. doi:10.1097/FTD.0b013e31803d3c04. PMID 17417081.
- Fraser, A. D.; Bryan, W. (1991). "Evaluation of the Abbott ADx and TDx Serum Benzodiazepine Immunoassays for Analysis of Alprazolam". Journal of Analytic Toxicology 15 (2): 63–65. doi:10.1093/jat/15.2.63. PMID 1675703.
- Baselt, R. (2011). Disposition of Toxic Drugs and Chemicals in Man (9th ed.). Seal Beach, CA: Biomedical Publications. pp. 45–48. ISBN 978-0-9626523-8-7.
- Skelton, K. H.; Nemeroff, C. B.; Owens, M. J. (2004). "Spontaneous Withdrawal from the Triazolobenzodiazepine Alprazolam Increases Cortical Corticotropin-Releasing Factor mRNA Expression". Journal of Neuroscience 24 (42): 9303–9312. doi:10.1523/JNEUROSCI.1737-04.2004. PMID 15496666.
- Chouinard, G. (2004). "Issues in the Clinical Use of Benzodiazepines: Potency, Withdrawal, and Rebound". Journal of Clinical Psychiatry 65 (Suppl 5): 7–12. PMID 15078112.
- White, G.; Gurley, D. A. (1995). "α Subunits Influence Zn Block of γ2 Containing GABAA Receptor Currents". NeuroReport 6 (3): 461–464. doi:10.1097/00001756-199502000-00014. PMID 7766843.
- Arvat, E.; Giordano, R.; Grottoli, S.; Ghigo, E. (2002). "Benzodiazepines and Anterior Pituitary Function". Journal of Endocrinological Investigation 25 (8): 735–747. doi:10.1007/bf03345110. PMID 12240908.
- Bentué-Ferrer, D.; Reymann, J. M.; Tribut, O.; Allain, H.; Vasar, E.; Bourin, M. (2001). "Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 11 (1): 41–50. doi:10.1016/S0924-977X(00)00137-1. PMID 11226811.
- "Alprazolam Dosage, Uses, Overdose Info and More". RXwiki.com. November 18, 2013. Retrieved 2014-01-22.[unreliable source?] ( Page will play audio when loaded)
- US patent 3987052, Jackson, H.B.
- DE 2012190, Jackson, H.B.
- Hester, J. B. Jr.; Duchamp, D. J.; Chidester, C. G. (1971). "A Synthetic Approach to New 1,4-Benzodiazepine Derivatives". Tetrahedron Letters 12 (20): 1609–1612. doi:10.1016/S0040-4039(01)87414-1.
- Meguro, K.; Natsugari, H.; Tawada, H.; Kuwada, Y. (1973). "Heterocycles. IV. Reactions of 2-Amino-3H-1, 4-benzodiazepines with Primary Amines and Hydroxylamines". Chemical & Pharmaceutical Bulletin 21 (11): 2366. doi:10.1248/cpb.21.2366.
- Meguro, K.; Kuwada, Y. (1973). "Heterocycles. V. Syntheses and Structures of 7-Chloro-2-hydrazino-5-phenyl-3H-1, 4-benzodiazepines and Some Isomeric 1, 4, 5-Benzotriazocines". Chemical & Pharmaceutical Bulletin 21 (11): 2375. doi:10.1248/cpb.21.2375.
- Meguro, K.; Tawada, H.; Miyano, H.; Sato, Y.; Kuwada, Y. (1973). "Heterocycles. VI. Syntheses of 4H-s-Triazolo [4, 3-a] [1, 4] benzodiazepines, Novel Tricyclic Psychosedatives". Chemical & Pharmaceutical Bulletin 21 (11): 2382. doi:10.1248/cpb.21.2382.
- Walser, A.; Zenchoff, G. (1977). "Quinazolines and 1,4-Benzodiazepines. 81. s-Triazolo[4,3-a][1,4]benzodiazepines by Oxidative Cyclization of Hydrazones". Journal of Medicinal Chemistry 20 (12): 1694–1697. doi:10.1021/jm00222a035. PMID 592339.
- US patent 3709898, Hester, J.
- US patent 3781289, Hester, J.
- Soumerai, S. B.; Simoni-Wastila, L.; Singer, C.; Mah, C.; Gao, X.; Salzman, C. et al. (2003). "Lack of Relationship between Long-Term Use of Benzodiazepines and Escalation to High Dosages". Psychiatric Services 54 (7): 1006–1011. doi:10.1176/appi.ps.54.7.1006. PMID 12851438.
- Licata, S. C.; Rowlett, J. K. (2008). "Abuse and Dependence Liability of Benzodiazepine-Type Drugs: GABAA Receptor Modulation and Beyond". Pharmacology Biochemistry and Behavior 90 (1): 74–89. doi:10.1016/j.pbb.2008.01.001. PMC 2453238. PMID 18295321.
- Goodnough, Abby (September 14, 2011). "Abuse of Xanax Leads a Clinic to Halt Supply". New York Times.
- Ballenger, J. C. (1984). "Psychopharmacology of the Anxiety Disorders". The Psychiatric Clinics of North America 7 (4): 757–771. PMID 6151647.
- Ciraulo, D. A.; Barnhill, J. G.; Greenblatt, D. J.; Shader, R. I.; Ciraulo, A. M.; Tarmey, M. F.; Molloy, M. A.; Foti, M. E. (1988). "Abuse Liability and Clinical Pharmacokinetics of Alprazolam in Alcoholic Men". The Journal of Clinical Psychiatry 49 (9): 333–337. PMID 3417618.
- Vorma, H.; Naukkarinen, H. H.; Sarna, S. J.; Kuoppasalmi, K. I. (2005). "Predictors of Benzodiazepine Discontinuation in Subjects Manifesting Complicated Dependence". Substance Use & Misuse 40 (4): 499–510. doi:10.1081/JA-200052433. PMID 15830732.
- Walker, B. M.; Ettenberg, A. (2003). "The Effects of Alprazolam on Conditioned Place Preferences Produced by Intravenous Heroin". Pharmacology, Biochemistry, and Behavior 75 (1): 75–80. doi:10.1016/S0091-3057(03)00043-1. PMID 12759115.
- "OSAM-O-GRAM Highlights of Statewide Drug Use Trends" (PDF). Ohio, US: Wright State University and the University of Akron. January 2008. Retrieved 2008-12-10.
- Griffiths, R. R.; Wolf, B. (1990). "Relative Abuse Liability of Different Benzodiazepines in Drug Abusers". Journal of Clinical Psychopharmacology 10 (4): 237–243. doi:10.1097/00004714-199008000-00002. PMID 1981067.
- Wang, E. C.; Chew, F. S. (2006). "MR Findings of Alprazolam Injection into the Femoral Artery with Microembolization and Rhabdomyolysis" (PDF). Radiology Case Reports 1 (3). doi:10.2484/rcr.v1i3.33.
- "DB00404 (Alprazolam)". Canada: DrugBank. 2008-06-26. Archived from the original on 6 July 2011. Retrieved 2011-07-12.
- Sheehan, M. F.; Sheehan, D. V.; Torres, A.; Coppola, A.; Francis, E. (1991). "Snorting benzodiazepines". The American Journal of Drug and Alcohol Abuse 17 (4): 457–468. doi:10.3109/00952999109001605. PMID 1684083.
- "INTELLIGENCE ALERT – XANAX BLOTTER PAPER IN BARTLESVILLE, OKLAHOMA" (Microgram Bulletin). US DEA. May 2008. Archived from the original on 2008-05-21.
- "Street Terms for Xanax". Axisresidentialtreatment.com. Retrieved 2014-02-14.
- "Street Names for Alprazolam". Alprazolamaddictionhelp.com. Retrieved 2014-02-14.
- "Xanax Effects and Withdrawal Symptoms". Drugrehabtreatmenthelp.com. 2010. Retrieved 2014-02-14.
- "Benzodiazepine Names". Non-benzodiazepines.org.uk. Archived from the original on 8 December 2008. Retrieved 2008-10-31.
- "Discontinuation of Xanax" (PDF). Pfizer Australia.
- "DEA, Drug Scheduling". DEA. Archived from the original on 4 November 2008. Retrieved 2008-10-31.
- "Misuse of Drugs Act 1971 (c. 38)". The UK Statute Law database. 1991.
- British Medical Association, Royal Pharmaceutical Society of Great Britain (September 2010). "4.1.2: Anxiolytics". British National Formulary (BNF 60). United Kingdom: BMJ Group and RPS Publishing. p. 212. ISBN 978-0-85369-931-6.
- "List of Psychotropic Substances under International Control" (PDF). Incb.org. International Narcotics Control Board. August 2003. Archived from the original on 17 December 2008. Retrieved 2008-12-07.
- "Misuse Of Drugs (Amendment) Regulations". Irish Statute Book. Office of the Attorney General. 1993.
- "Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" [Medical Products Agency on the lists of drugs] (PDF) (in Swedish). Sweden: Läkemedelsverket. October 2011.
- "Alprazolam to be rescheduled from next year". 2013.
|Wikimedia Commons has media related to Alprazolam.|
- U.S. National Library of Medicine: Drug Information Portal – Alprazolam
- Erowid Alprazolam (Xanax) Research